CL-316243 is a selective and highly specific β3-adrenoceptor agonist. CL 316243 possesses anti-obesity and anti-diabetic effects due to increasing brown adipose tissue thermogenesis and metabolic rate, and consequently may be useful for treating obesity as well as non-insulin-dependent diabetes mellitus in obese persons, without causing excessive side effects.

(R)-Bambuterol is a selective β2-adrenoceptor agonist. R-Bambuterol Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currenTLy on the market. Laevo-Bambuterol was approved by the China Food and Drug Administration for the treatment of asthma.

Protopine is the isoquinoline alkaloid found primarily in the plant families Berberidaceae, Ranunculaceae, Rutaceae, Fumariaceae. It has diverse biological activities, such as anti-thrombotic, anti-inflammatory, anti-parasitic activity, antimicrobial activity, as well as hepatoprotective effects in animal models. The biological activities of protopine are associated with its ability selectively inhibits K(ATP) channels by targeting on SUR1 subunit. In addition, was discovered that β2 -adrenoceptor (β2 -AR) is a target for antiasthma activities of protopine. On this target, binding of the drug occurs on the amino acid residual of Ser 169 through the formation of hydrogen bonds and receptor‐drug bumps.

Capsanthin, the red xanthophyll pigment, is used as a food additive approved by the European Union (EU) under the name as E160c. The common names for E160c are paprika extract, capsanthin or capsorubin. Capsanthin shows potent anti-adipogenic, lipolytic and fatty acid burning activities due to its potent adrenoceptor-beta2-agonistic activity. It was revealed, that capsanthin was not a thermogenic substance that is why it may be a good candidate for the development of new bioactive agent effective as a new anti-obese or insulin sensitivity enhancing substance.

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.